Northwell Nurse Sandra Lindsay is 1st for Pfizer COVID Vaccine – Again

The first American to receive the COVID-19 vaccine in 2020 repeated the feat again today as part of a public health awareness event. Sandra Lindsay, RN, became a global phenomenon on December 14, 2020, when the Northwell Health critical care nurse director received the Pfizer-BioNTech COVID-19 vaccine.

Nearly three years later, Nurse Lindsay volunteered to be the first American to receive this season’s shot: Pfizer-BioNTech 2023-24 COVID-19 vaccine. This mRNA formulation offers protection against BA.2, BA.2.86 “Pirola,” EG.5 “Eris,” XBB.1.5 COVID variants – needed immunity as COVID hospitalizations begin to rise ahead of the fall and winter season.

Despite serving on the front lines of the pandemic, Nurse Lindsay has yet to be infected with COVID-19. “It’s important that people understand that COVID is still around and can still severely affect an individual,” said Nurse Lindsay. “Having worked through the darkest days of the pandemic and seen the devastating effects it can have, I tell people not to take chances. We have powerful weapons like vaccines to prevent those devastating outcomes.”

This was the third COVID-19 vaccine – and sixth, including boosters – taken by Nurse Lindsay, who has since been elevated to the role of vice president of public health advocacy at Northwell. The FDA approved Pfizer’s vaccine on Monday followed by the CDC’s Advisory Committee on Immunization Practices on Tuesday.

Michelle Chester, FNP-BC, DNP, senior director of Employee Health Services at Northwell, administered the shot. She also gave Nurse Lindsay the vaccine in 2020. Also joining Nurse Lindsay in receiving vaccinations were: Adam Berman, MD, associate chair of emergency medicine at Long Island Jewish Medical Center in New Hyde Park; Mozhdeh Mehrabian, a respiratory therapist at North Shore University Hospital in Manhasset; and Mangala Narasimhan, MD, senior vice president of critical care services at Northwell.

“Vaccination is and has proven to be an important tool to fight against the severity of COVID-19,” said Jill Kalman, MD, chief medical officer and deputy physician in chief at Northwell Health. “We’re here now to reinforce that there is extra protection available against the newest COVID-19 variants as the FDA and CDC have approved a new seasonal vaccine.”

Northwell has administered about 800,000 doses of COVID-19 vaccine since the end of 2020. The FDA and CDC have said the vaccine is safe and effective for anyone ages 6 months and older. Northwell Health will offer both Pfizer and Moderna vaccines to its employees and the general public through its ambulatory network once it receives doses.

“It’s been three-and-a-half years since COVID hit the world and we have not forgotten,” said Bruce Farber, MD, chief of public health and epidemiology at Northwell. “At the peak of the First Wave, our health system had nearly 3,500 hospitalized COVID patients. This week, it’s less than 200. Even though that number has bumped up considerable since July, the majority are incidental cases, meaning that they have been hospitalized for some other reason. Nevertheless, COVID causes at lot of morbidity and it interrupts lives. That’s why we support vaccines as a major way to prevent COVID.”

Dr. Farber also warned of a surge later this fall and into the winter – another possible “tripledemic” of COVID, flu and RSV – unless Americans embrace vaccines. Flu and COVID vaccines can be taken at the same time. RSV is also available and should be considered for at-risk populations.

Northwell Health is New York State’s largest health system and private employer.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”